G Coukos
Overview
Explore the profile of G Coukos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1640
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin-Lluesma S, Svane I, Dafni U, Vervita K, Karlis D, Dimopoulou G, et al.
Ann Oncol
. 2024 Jul;
35(10):860-872.
PMID: 39053767
Background: Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL-ACT) has consistently shown efficacy in advanced melanoma. New results in the field provide now the opportunity to assess overall survival (OS) after...
2.
Rusakiewicz S, Tyekucheva S, Tissot-Renaud S, Chaba K, Imbimbo M, Benedetti F, et al.
Eur J Cancer
. 2024 Feb;
200:113535.
PMID: 38309015
Background: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer (BC) subtype, with dismal prognosis and limited option in advanced settings, yet stromal tumor infiltrating lymphocytes (sTILs) in this...
3.
Gavrielatou N, Fortis E, Spathis A, Anastasiou M, Economopoulou P, Foukas G, et al.
Ann Oncol
. 2023 Dec;
35(4):340-350.
PMID: 38159908
Background: Programmed cell death protein 1 (PD-1) axis blockade has become the mainstay in the treatment of recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Programmed death-ligand...
4.
Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, et al.
Eur J Cancer
. 2021 Apr;
149:153-164.
PMID: 33865201
Background: Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy but frequently cause immune-related adverse events (irAEs). Description of late-onset and duration of irAEs in the literature is often incomplete. Methods:...
5.
Dafni U, Martin-Lluesma S, Balint K, Tsourti Z, Vervita K, Chenal J, et al.
Eur J Cancer
. 2020 Nov;
142:63-82.
PMID: 33221598
Background: Therapeutic cancer vaccination is an area of interest, even though promising efficacy has not been demonstrated so far. Design: A systematic review and meta-analysis was conducted to evaluate vaccines'...
6.
Delage J, Faivre-Chauvet A, Fierle J, Gnesin S, Schaefer N, Coukos G, et al.
EJNMMI Res
. 2020 Aug;
10(1):98.
PMID: 32804276
Purpose: TEM-1 (tumor endothelial marker-1) is a single-pass transmembrane cell surface glycoprotein expressed at high levels by tumor vasculature and malignant cells. We aimed to perform a preclinical investigation of...
7.
Wagner A, Oertelt-Prigione S, Adjei A, Buclin T, Cristina V, Csajka C, et al.
Ann Oncol
. 2019 Oct;
30(12):1914-1924.
PMID: 31613312
Background: The importance of sex and gender as modulators of disease biology and treatment outcomes is well known in other disciplines of medicine, such as cardiology, but remains an undervalued...
8.
Dafni U, Michielin O, Lluesma S, Tsourti Z, Polydoropoulou V, Karlis D, et al.
Ann Oncol
. 2019 Oct;
30(12):1902-1913.
PMID: 31566658
Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) has been tested in advanced melanoma patients at various centers. We conducted a systematic review and meta-analysis to assess its efficacy...
9.
Digklia A, Duran R, Homicsko K, Kandalaft L, Hocquelet A, Orcurto A, et al.
Cardiovasc Intervent Radiol
. 2018 Sep;
42(9):1221-1229.
PMID: 30209564
The therapeutic options in the treatment of cancer therapy have been recently significantly increased with systemic immune-targeted therapies. Novel immunotherapy approaches based on immune checkpoint blockade or engineered cytotoxic T...
10.
Guo Y, Hu J, Wang Y, Peng X, Min J, Wang J, et al.
Eur J Cancer
. 2018 Jan;
90:111-121.
PMID: 29304474
Background: Tumour endothelial marker 1 (TEM1/endosialin/CD248) is a tumour-restricted cell-surface protein expressed by human sarcomas. We previously developed a high-affinity human single-chain variable fragment (scFv)-Fc fusion protein (78Fc) against TEM1...